Becoming a Partner of Choice and Evaluating Prospective Alliances

by David Wallis, Dechert and Jan Heybroek Whether you're on the inlicensing or outlicensing side of a collaboration, attention must be paid to putting forth the right image and learning about your prospective partners before the alliance is struck.

Related Content:

PartnershipsBioPharm International-02-01-2003

AGC Biologics to Supply More Plasmid DNA for Pfizer-BioNTech COVID-19 Vaccine

Industry Consortiums Work to Tackle COVID-19

Lonza and Moderna to Expand Their COVID-19 Vaccine Drug Substance Manufacturing Collaboration